BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) is a global biotechnology firm dedicated to converting genetic insights into targeted treatments for rare and severe disorders. The company commercializes eight key products, including Vimizim, Naglazyme, Palynziq, Brineura, Aldurazyme, Roctavian, Kuvan, and Voxzogo, addressing conditions such as lysosomal storage disorders, phenylketonuria, achondroplasia, and severe hemophilia A. Roctavian is a gene therapy aimed at restoring factor VIII levels in hemophilia A patients, while Voxzogo focuses on growth-related disorders. In addition, BioMarin has a broad clinical and preclinical pipeline featuring programs such as Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701, with INZ-701 positioned as a late-stage enzyme replacement therapy for ENPP1 deficiency.

As per US Inflation Report published on ‘BMRN’ on Feb 27, 2026, Kalkine provided an ‘Buy’ stance on the stock at USD 61.11 based on fundamental analysis.

Noted below are the details of support and resistance levels provided in our previous report:

Rationale:

Despite delivering double-digit revenue growth and a Q4 revenue beat, BioMarin’s outlook appears tempered by a notable miss on full-year EPS expectations, signaling pressure on profitability. The discontinuation of mid-stage Voxzogo trials due to safety concerns introduces clinical uncertainty and could delay expansion into additional indications, while rising competition in achondroplasia and broader regulatory scrutiny may further constrain growth. Although pipeline progress and the Amicus acquisition offer long-term potential, near-term execution risks, margin pressures, and limited earnings visibility suggest current levels may already reflect much of the upside.

Valuation (Using P/E Multiple)

Share Price Chart

Conclusion

Given a miss on full-year EPS expectations, coupled with pipeline disruptions and rising competitive intensity, a "Sell" is recommendation on BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has been given at the current market price of USD 56.58 as on 09 April 2026 at 11:55 AM PDT.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 09 April 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.